Celltech Therapeutics Limited

Celltech Limited

Celltech R&d Limited

Hoechst Aktiengesellschaft

Solvay Sa

Mark William Bodmer

Diljeet Singh Athwal

John Spencer Emtage

John Robert Adair

Raymond John Owens

Nigel Richard Whittle

Gregory Paul Winter

Jerald C Sadoff

Ulrich Gebert

Lutz Riechmann

Hiristo Anagnostopulos

Heinz Hanel

Michael Limbert

Geoffrey Thomas Yarranton

Andrew Mountain

Alan Howard Lyons

Gerald Anthony Higgs

Steven Michael Opal

Alan S Cross

Susan Adrienne Morgan

An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.

Interleukin-5 specific recombinant antibodies

Nucleic acids encoding interleukin-5 specific recombinant antibodies

An antibody to tumor necrosis factor-&agr; (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each of the components are therefore of utility in therapy of sepsis. The anti-LPS antibody included may be specific for the O-specific clain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognizes the core glycolipid of lipopolysaccharide.

Pharmaceutical product for the treatment of sepsis

The invention describes humanized antibodies having specificity for the epitope recognised by the murine monoclonal antibody L243. Also described are processes for preparing said antibodies and pharmaceutical compositions and medical uses of said antibodies.

Humanized antibodies

Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.

Recombinant antibodies specific for TNF.alpha.

Methods for preparing Fv fragments which lack linking polypeptides in eukaryotic cells are provided.

Method for producing Fv fragments in eukaryotic cells

A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy of prophylaxis of disorders associated with undesirable high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1(5-oxo-hexyl)xanthine (known as Pentoxifylline or TRENTAL) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanized recombinant antibody or fragment.

Use of antibodies to TNF or fragments derived thereof and xanthine

The present invention provides humanized antibody molecules (HAMs) having specificity for carcinoembryonic antigen (CEA) and having an antigen binding site wherein at least one of the complementarity determining regions (CDRs) of the variable domains is derived from the mouse monoclonal antibody A5B7 (A5B7 MAB) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The HAMs may be chimeric humanized antibodies or CDR-grafted humanized antibodies and are preferably produced by recombinant DNA techniques. The HAMs are useful for in vivo diagnosis and therapy.

CDR grafted anti-CEA antibodies and their production

The present invention provides an altered antibody molecule (AAM) having a hinge region which has a different number of cysteine residues from that found in the hinge region normally associated with the CH1 domain of the antibody molecule and a process for producing the same using recombinant DNA technology.

Recombinant antibody

Recombinant antibodies and methods for their production in which surface

Growing community of inventors

South Hinksey, United Kingdom

Mark William Bodmer